Effect of Sarilumab on Patient-reported Outcomes in Patients With Active Rheumatoid Arthritis and With Inadequate Response or Intolerance to Current Conventional Synthetic DMARDs or Tumor Necrosis Factor Inhibitors
Phase of Trial: Phase IV
Latest Information Update: 03 Sep 2019
Price : $35 *
At a glance
- Drugs Sarilumab (Primary) ; Azathioprine; Chloroquine; Hydroxychloroquine; Leflunomide; Methotrexate; Methotrexate; Sulfasalazine
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms SariPRO
- Sponsors Sanofi
- 26 Aug 2019 Status changed from active, no longer recruiting to completed.
- 30 Jan 2019 Planned End Date changed from 31 Jul 2019 to 1 Aug 2019.
- 30 Jan 2019 Planned primary completion date changed from 31 Jul 2019 to 1 Aug 2019.